Question

I am a breastfeeding mother and i want to know if it is safe to use NSC 683769? Is NSC 683769 safe for nursing mother and child? Does NSC 683769 extracts into breast milk? Does NSC 683769 has any long term or short term side effects on infants? Can NSC 683769 influence milk supply or can NSC 683769 decrease milk supply in lactating mothers?

NSC 683769 lactation summary

NSC 683769 is safe in breastfeeding
  • DrLact safety Score for NSC 683769 is 1 out of 8 which is considered Safe as per our analyses.
  • A safety Score of 1 indicates that usage of NSC 683769 is mostly safe during lactation for breastfed baby.
  • Our study of different scientific research also indicates that NSC 683769 does not cause any serious side effects in breastfeeding mothers.
  • Most of scientific studies and research papers declaring usage of NSC 683769 safe in breastfeeding are based on normal dosage and may not hold true for higher dosage.
  • Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.

Answer by Dr. Ru: About NSC 683769 usage in lactation

Biliary salt that appears in low amount in the serum because it is absorbed to the portal circulation and completely excreted into biliary duct. Excreted into breast milk in non-significant amount with no side-effects being observed among infants of treated mothers. Medication that has been used for treatment of newborns and older infants.

Answer by DrLact: About NSC 683769 usage in lactation

Because of the low levels of NSC 683769 (ursodeoxycholic acid) in breastmilk, amounts ingested by the infant are small and are not expected to cause any adverse effects in breastfed infants. No special precautions are required.

NSC 683769 Side Effects in Breastfeeding

One breastfed (extent not stated) infant developed normally over the first 6 months of life during maternal NSC 683769 therapy of 750 to 1000 mg daily.[1] Seven women who were taking NSC 683769 14 mg/kg daily near term and postpartum. They reported no adverse reactions in their breastfed infants during the early postpartum period.[2] A mother receiving oral NSC 683769 250 mg 3 times daily for primary biliary cirrhosis reportedly breastfed her infant normally, although the extent and duration of breastfeeding was not stated.[4] A woman with primary biliary cirrhosis developed severe pruritus and elevated serum bile acids 3 weeks postpartum. NSC 683769 was started at a dose of 500 mg (7.5 mg/kg) daily, increasing to 1500 mg (25 mg/kg) daily over the next 8 weeks. Psychomotor development of her breastfed (extent not stated) infant was normal, and no apparent side effects were observed in the infant.[3] A woman was breastfeeding her 8-day-old preterm infant 10 times daily for about 15 minutes each time. The infant was born by cesarean section at 34 weeks of gestation with a weight of 3600 grams,. She was diagnosed with cholestasis, type 1 diabetes, and hypothyroidism. She was treated with NSC 683769 500 mg daily, insulin levemir and aspart, and levothyroxine. She was also taking cefuroxime, flurbiprofen, a combination of acetaminophen, propyphenazone, and caffeine. The mother took the NSC 683769 for a total of 12 days, cefuroxime and the analgesic combination for 10 days and flurbiprofen for 15 days. No adverse effects were noticed during the period of NSC 683769 treatment.[5]
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. We do not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.